FAQ on Tonix Pharmaceuticals' Q1 2025 Results and Fibromyalgia Drug Approval Prospects
Summary
What is TNX-102 SL and what is its significance?
TNX-102 SL is a non-opioid analgesic developed by Tonix Pharmaceuticals for the treatment of fibromyalgia. Its approval would represent the first new drug class for fibromyalgia in over 15 years, offering a potential new treatment option for patients.
When is the FDA expected to make a decision on TNX-102 SL?
The FDA’s decision on TNX-102 SL is anticipated by the PDUFA goal date of August 15, 2025.
What were Tonix Pharmaceuticals’ financial results for Q1 2025?
Tonix Pharmaceuticals ended Q1 2025 with $131.7 million in cash and cash equivalents, reporting a net loss of $16.8 million on $2.4 million in product revenue.
What other developments are in Tonix Pharmaceuticals’ pipeline?
Tonix Pharmaceuticals reported positive Phase 1 data for TNX-1500 in kidney transplant rejection and strong preclinical results for TNX-801, a live-virus vaccine targeting mpox and smallpox, among other pipeline progress.
What is the Fast Track designation for TNX-102 SL?
The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia, indicating its potential to address an unmet medical need and expediting its review process.
How can I find more information about Tonix Pharmaceuticals?
For more information about Tonix Pharmaceuticals, visit their website at www.TonixPharma.com or check the latest news in the company’s newsroom at https://ibn.fm/TNXP.
What is the significance of the DoD contract awarded to Tonix Pharmaceuticals?
The U.S. Department of Defense awarded Tonix Pharmaceuticals a contract for up to $34 million over five years to develop TNX-4200, aimed at improving medical readiness against biological threats, highlighting the company’s role in addressing public health challenges.
What products does Tonix Medicines currently market?
Tonix Medicines markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 113504